Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
Tuesday, July 09, 2024SELLAS Life Sciences Group Inc a latestage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
Ligand to Acquire APEIRON Biologics AG for $100 Million
Monday, July 08, 2024Ligand Pharmaceuticals Incorporated today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG which holds royalty rights to QARZIBA for the treatment of highrisk neuroblastoma for million in cash In addition Li...
Tagrisso With the Addition of Chemotherapy Approved in the EU as New 1st-line Treatment for Patients With EGFR-mutated Advanced Lung Cancer
Saturday, July 06, 2024AstraZenecas Tagrisso with the addition of pemetrexed and platinumbased chemotherapy has been approved in the European Union for the stline treatment
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Friday, July 05, 2024Genentech a member of the Roche Group announced today that the Phase IIIII SKYSCRAPER study evaluating tiragolumab plus Tecentriq and chemotherapy
GSK and CureVac to restructure collaboration into new licensing agreement
Thursday, July 04, 2024GSK plc and CureVac NV today announced they have restructured their existing collaboration into a new licensing agreement allowing each company to prioritise investment and focus their respective mRNA development activities
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
Thursday, July 04, 2024Regeneron Pharmaceuticals Inc and Sanofi today announced that the European Commission has approved Dupixent as an addon maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
Wednesday, July 03, 2024Fresenius via its operating company Fresenius Kabi announced today the immediate availability in the US of its biosimilar Tyenne in a subcutaneous
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Wednesday, July 03, 2024Vertex Pharmaceuticals Incorporated today announced that the US Food and Drug Administration has accepted its New Drug Application for investigational
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Wednesday, July 03, 2024Heron Therapeutics Inc a commercialstage biotechnology company today announced that the FDA acknowledged the receipt of the Companys Prior
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Wednesday, July 03, 2024The US Food and Drug Administration approved Kisunla Eli Lilly and Companys Alzheimers treatment for adults with early symptomatic Alzheimers disease which includes people with mild cognitive impairment as well as people
